Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Scutellarin Suppresses RPMI7951 Melanoma Cell Proliferation by Targeting TOPK

Author(s): Xin Mu, Lijuan Wang, Zixi Zhang, Rui Ge, Jian Zhang, Wenli Liu, Kuanhou Mou and Shemin Lv*

Volume 21, Issue 5, 2021

Published on: 11 August, 2020

Page: [640 - 648] Pages: 9

DOI: 10.2174/1871520620666200811112156

Price: $65

conference banner
Abstract

Background: T-LAK cell-Originated Protein Kinase (TOPK) belongs to the serine/threonine protein kinase family. It is highly expressed in RPMI7951 melanoma cells. Scutellarin (SCU) is an active ingredient extracted from Erigeron breviscapus (Vant.) Hand.–Mazz. Its main physiological functions are related to its anti-inflammatory and antitumour activities.

Methods: The relationship between SCU and TOPK was assessed by molecular docking, an in vitro binding assay and an in vitro kinase assay. The effect of SCU on RPMI7951 cells was detected by MTS and soft agar assays. TOPK knockdown was induced by lentiviral infection. The TOPK downstream signalling pathway was detected by western blot and immunohistochemical analyses in vitro and in vivo.

Results: SCU was found to directly bind with TOPK and inhibit TOPK activity in vitro. SCU inhibited the proliferation and colony formation of RPMI7951 cells in a dose-dependent manner. Silencing TOPK decreased the sensitivity of colon cancer cells to SCU. SCU inhibited the phosphorylation levels of Extracellular Regulated protein Kinases 1/2 (ERK1/2) and histone H3 in a time- and dose-dependent manner in RPMI7951 cells. In addition, SCU inhibited the growth of xenograft tumours of RPMI7951 cells and decreased the phosphorylation levels of extracellular regulated protein kinases 1/2 and histone H3 in vivo.

Conclusion: The results showed that SCU exerts promising antitumour effects on human RPMI7951 cells by inhibiting the activity of TOPK.

Keywords: Scutellarin, TOPK, RPMI7951, melanoma, ERK, histone H3.

« Previous Next »
Graphical Abstract

[1]
Fan, X.; Tao, J.; Fredimoses, M.; Wu, J.; Jiang, Z.; Zhang, K.; Zhang, X.; Li, S. Eupafolin suppresses esophagus cancer growth by targeting T-LAK cell-originated protein kinase. Front. Pharmacol., 2019, 10, 1248.
[http://dx.doi.org/10.3389/fphar.2019.01248] [PMID: 31708778]
[2]
Abe, Y.; Matsumoto, S.; Kito, K.; Ueda, N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J. Biol. Chem., 2000, 275(28), 21525-21531.
[http://dx.doi.org/10.1074/jbc.M909629199] [PMID: 10781613]
[3]
Xu, M.; Xu, S. PBK/TOPK overexpression and survival in solid tumors: A PRISMA-compliant meta-analysis. Medicine (Baltimore), 2019, 98(10), e14766.
[http://dx.doi.org/10.1097/MD.0000000000014766] [PMID: 30855480]
[4]
Ishikawa, C.; Senba, M.; Mori, N. Mitotic kinase PBK/TOPK as a therapeutic target for adult T cell leukemia/lymphoma. Int. J. Oncol., 2018, 53(2), 801-814.
[http://dx.doi.org/10.3892/ijo.2018.4427] [PMID: 29901068]
[5]
Uchida, E.; Suwa, S.; Yoshimoto, R.; Watanabe, K.; Kasama, T.; Miura, O.; Fukuda, T. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation. Int. J. Oncol., 2019, 54(5), 1785-1796.
[http://dx.doi.org/10.3892/ijo.2019.4740] [PMID: 30864683]
[6]
Roh, E.; Lee, M.H.; Zykova, T.A.; Zhu, F.; Nadas, J.; Kim, H.G.; Bae, K.B.; Li, Y.; Cho, Y.Y.; Curiel-Lewandrowski, C.; Einspahr, J.; Dickinson, S.E.; Bode, A.M.; Dong, Z. Targeting PRPK and TOPK for skin cancer prevention and therapy. Oncogene, 2018, 37(42), 5633-5647.
[http://dx.doi.org/10.1038/s41388-018-0350-9] [PMID: 29904102]
[7]
Seol, M.A.; Park, J.H.; Jeong, J.H.; Lyu, J.; Han, S.Y.; Oh, S.M. Role of TOPK in lipopolysaccharide-induced breast cancer cell migration and invasion. Oncotarget, 2017, 8(25), 40190-40203.
[http://dx.doi.org/10.18632/oncotarget.15360] [PMID: 28212583]
[8]
Lu, S.; Ye, L.; Yin, S.; Zhao, C.; Yan, M.; Liu, X.; Cui, J.; Hu, H. Glycyrol exerts potent therapeutic effect on lung cancer via directly inactivating T-LAK cell-originated protein kinase. Pharmacol. Res., 2019, 147, 104366.
[http://dx.doi.org/10.1016/j.phrs.2019.104366] [PMID: 31377221]
[9]
Song, X.; Yin, S.; Zhang, E.; Fan, L.; Ye, M.; Zhang, Y.; Hu, H. Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase. Oncotarget, 2016, 7(40), 65732-65743.
[http://dx.doi.org/10.18632/oncotarget.11610] [PMID: 27582549]
[10]
Ohashi, T.; Komatsu, S.; Ichikawa, D.; Miyamae, M.; Okajima, W.; Imamura, T.; Kiuchi, J.; Nishibeppu, K.; Kosuga, T.; Konishi, H.; Shiozaki, A.; Fujiwara, H.; Okamoto, K.; Tsuda, H.; Otsuji, E. Overexpression of PBK/TOPK contributes to tumor development and poor outcome of esophageal squamous cell carcinoma. Anticancer Res., 2016, 36(12), 6457-6466.
[http://dx.doi.org/10.21873/anticanres.11244] [PMID: 27919968]
[11]
Lu, H.; Xiao, J.; Ke, C.; Ni, X.; Xiu, R.; Tian, Q.; Pan, H.; Zou, L.; Wang, F.; Ma, T.; Ji, X.; Yuan, P.; Liu, L.; Zhang, J.; Jia, W.; Duan, Q.; Zhu, F. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. Cell Death Dis., 2019, 10(8), 583.
[http://dx.doi.org/10.1038/s41419-019-1805-9] [PMID: 31378785]
[12]
Yang, J.; Yuan, D.; Xing, T.; Su, H.; Zhang, S.; Wen, J.; Bai, Q.; Dang, D. Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase. J. Ginseng Res., 2016, 40(4), 400-408.
[http://dx.doi.org/10.1016/j.jgr.2016.03.007] [PMID: 27746693]
[13]
Zhu, F.; Zykova, T.A.; Kang, B.S.; Wang, Z.; Ebeling, M.C.; Abe, Y.; Ma, W.Y.; Bode, A.M.; Dong, Z. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology, 2007, 133(1), 219-231.
[http://dx.doi.org/10.1053/j.gastro.2007.04.048] [PMID: 17631144]
[14]
Park, J.H.; Lin, M.L.; Nishidate, T.; Nakamura, Y.; Katagiri, T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res., 2006, 66(18), 9186-9195.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-1601] [PMID: 16982762]
[15]
Matsuo, Y.; Park, J.H.; Miyamoto, T.; Yamamoto, S.; Hisada, S.; Alachkar, H.; Nakamura, Y. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci. Transl. Med., 2014, 6(259), 259ra145.
[http://dx.doi.org/10.1126/scitranslmed.3010277] [PMID: 25338756]
[16]
Yuan, Y.; Zha, H.; Rangarajan, P.; Ling, E.A.; Wu, C. Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. BMC Neurosci., 2014, 15, 125.
[http://dx.doi.org/10.1186/s12868-014-0125-3] [PMID: 25416145]
[17]
Sun, C.Y.; Nie, J.; Zheng, Z.L.; Zhao, J.; Wu, L.M.; Zhu, Y.; Su, Z.Q.; Zheng, G.J.; Feng, B. Renoprotective effect of scutellarin on cisplatin-induced renal injury in mice: Impact on inflammation, apoptosis, and autophagy. Biomed. Pharmacother., 2019, 112, 108647.
[18]
Sun, C.; Li, C.; Li, X.; Zhu, Y.; Su, Z.; Wang, X.; He, Q.; Zheng, G.; Feng, B. Scutellarin induces apoptosis and autophagy in NSCLC cells through ERK1/2 and AKT signaling pathways in vitro and in vivo. J. Cancer, 2018, 9(18), 3247-3256.
[http://dx.doi.org/10.7150/jca.25921] [PMID: 30271483]
[19]
Deng, W.; Han, W.; Fan, T.; Wang, X.; Cheng, Z.; Wan, B.; Chen, J. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN. Biomed. Pharmacother., 2018, 107, 1505-1513.
[http://dx.doi.org/10.1016/j.biopha.2018.08.127]
[20]
Zhu, P.T.; Mao, M.; Liu, Z.G.; Tao, L.; Yan, B.C. Scutellarin suppresses human colorectal cancer metastasis and angiogenesis by targeting ephrinb2. Am. J. Transl. Res., 2017, 9(11), 5094-5104.
[PMID: 29218107]
[21]
Li, C.Y.; Wang, Q.; Wang, X.; Li, G.; Shen, S.; Wei, X. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway. Eur. J. Pharmacol., 2019, 858, 172463.
[http://dx.doi.org/10.1016/j.ejphar.2019.172463] [PMID: 31211986]
[22]
Zykova, T.A.; Zhu, F.; Lu, C.; Higgins, L.; Tatsumi, Y.; Abe, Y.; Bode, A.M.; Dong, Z. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin. Cancer Res., 2006, 12(23), 6884-6893.
[23]
Kim, D.J.; Li, Y.; Reddy, K.; Lee, M.H.; Kim, M.O.; Cho, Y.Y.; Lee, S.Y.; Kim, J.E.; Bode, A.M.; Dong, Z. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res., 2012, 72(12), 3060-3068.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3851] [PMID: 22523035]
[24]
Saraya, T.; Light, R.W.; Fujiwara, M.; Takizawa, H. Diagnostic clue for pleural metastasis of malignant melanoma. J. Gen. Family Med., 2018, 19(6), 217-218.
[http://dx.doi.org/10.1002/jgf2.200]
[25]
Gastman, B.R.; Gerami, P.; Kurley, S.J.; Cook, R.W.; Leachman, S.; Vetto, J.T. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J. Am. Acad. Dermatol., 2019, 80(1), 149-157.
[26]
Clark, W.H., Jr; Elder, D.E.; Guerry, D., IV; Epstein, M.N.; Greene, M.H.; Van Horn, M. A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol., 1984, 15(12), 1147-1165.
[http://dx.doi.org/10.1016/S0046-8177(84)80310-X] [PMID: 6500548]
[27]
Matsumoto, S.; Abe, Y.; Fujibuchi, T.; Takeuchi, T.; Kito, K.; Ueda, N.; Shigemoto, K.; Gyo, K. Characterization of a MAPKK-like protein kinase TOPK. Biochem. Biophys. Res. Commun., 2004, 325(3), 997-1004.
[http://dx.doi.org/10.1016/j.bbrc.2004.10.133] [PMID: 15541388]
[28]
Zykova, T.A.; Zhu, F.; Vakorina, T.I.; Zhang, J.; Higgins, L.A.; Urusova, D.V.; Bode, A.M.; Dong, Z. T-LAK cell-Originated Protein Kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. J. Biol. Chem., 2010, 285(38), 29138-29146.
[http://dx.doi.org/10.1074/jbc.M110.135905] [PMID: 20647304]
[29]
Herbert, K.J.; Ashton, T.M.; Prevo, R.; Pirovano, G.; Higgins, G.S. T-LAK cell-Originated Protein Kinase (TOPK): An emerging target for cancer-specific therapeutics. Cell Death Dis., 2018, 9(11), 1089.
[http://dx.doi.org/10.1038/s41419-018-1131-7] [PMID: 30356039]

Rights & Permissions Print Cite
Article Metrics
35
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy